Abstract 3128
Background
Recurrent Respiratory papillomatosis (RRP) can result in significant morbidity due to effects on voice and breathing and often requires frequent debulking procedures, which can disrupt quality of life. Responses to current surgical and medical treatments are inconsistent and there are no systemic treatments proven to be consistently effective in managing this disease. Bevacizumab, an anti-angiogenic agent that targets the vascular endothelial growth factor (VEGF) has been used as systemic agent for the treatment of RRP. We present a retrospective analysis of safety, efficacy and clinical outcomes in thirteen patients who were treated with systemic bevacizumab.
Methods
We present a retrospective analysis of patients with severe RRP who received 10mg/kg or 15mg/kg systemic bevacizumab at 3 weekly intervals at a single academic tertiary care center. They were monitored for toxicity and response to treatment as measured by need for further surgical interventions and improvement of symptoms.
Results
Twelve patients received at least 2 doses of systemic bevacizumab for an average of 5 cycles. Overall the treatment was well tolerated with minimal side effects. The most common side effect was hypertension, which was experienced by 4 out of 12 patients. Two patients discontinued treatment due to side effects. One experienced grade 3 epistaxis and another patient developed hypertension and thrombocytopenia. Two other individuals tolerated treatment well however, therapy was suspended due to insurance denial. All patients reported an improvement in symptoms including, improved quality of voice and breathing as well as decreased cough. The average number of surgical interventions in the year prior to administration of systemic bevacizumab was 4, with most individuals requiring intervention at a frequency of 2-4 months. Following treatment, only 4 of the 12 patients required one surgical intervention.
Conclusions
Systemic bevacizumab appears to be a safe and well tolerated treatment option for patients with severe RRP. It demonstrates promising efficacy on symptoms including voice quality and improved breathing as well as decreased requirement for surgical therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5544 - Evaluation of a radiomic signature of CD8 cells in patients treated with immunotherapy-radiotherapy in three clinical trials.
Presenter: Roger Sun
Session: Poster Display session 3
Resources:
Abstract
1117 - Biomarkers predictive of overall survival in advanced cancer patients treated with a peptide-based cancer vaccine.
Presenter: Shigetaka Suekane
Session: Poster Display session 3
Resources:
Abstract
1922 - Expression of PD-L1 in plasma exosomes of NSCLC patients and its associations with PD-L1 expression of corresponding tumor tissues
Presenter: Shaorong Yu
Session: Poster Display session 3
Resources:
Abstract
5495 - Patient’s perspective on digital biomarkers in advanced urologic malignancies
Presenter: Severin Rodler
Session: Poster Display session 3
Resources:
Abstract
3166 - A comprehensive Pan-cancer study of FGFR Aberrations in Chinese cancer patients
Presenter: Yang Gao
Session: Poster Display session 3
Resources:
Abstract
3277 - A Systemic Inflammation Response Index (SIRI) correlates with survival and could be a Predictive Factor for mFOLFIRINOX in Metastatic Pancreatic Cancer (PC)
Presenter: Vilma Pacheco-Barcia
Session: Poster Display session 3
Resources:
Abstract
2680 - Circulating biomarkers and risk of immune-related adverse events (irAEs) in patients (pts) with advanced Non-small cell lung cancer (aNSCLC) and metastatic melanoma (mMel)
Presenter: Alberto Pavan
Session: Poster Display session 3
Resources:
Abstract
4066 - Breast cancer in young women of Kazakh population depending on germline mutations: results of next-generation sequencing
Presenter: Dilyara Kaidarova
Session: Poster Display session 3
Resources:
Abstract
5514 - Discovery of an ImmunoTranscriptomics signature in blood for early colorectal cancer detection
Presenter: Paolo Angelino
Session: Poster Display session 3
Resources:
Abstract
1595 - Serum Netrin-1 as a Biomarker for Colorectal Cancer Detection
Presenter: Jinzhou Zhu
Session: Poster Display session 3
Resources:
Abstract